Chinese Journal of Dermatology ›› 2023, e20220368.doi: 10.35541/cjd.20220368

• Reviews • Previous Articles     Next Articles

Progress in treatment of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis

Zhan Jinshan, Xuan Xiuyun, Cao Juanmei, Chen Fangqi, Huang Changzheng   

  1. Department of Dermatology, Union Hospital affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
  • Received:2022-05-23 Revised:2022-12-20 Online:2023-01-05 Published:2023-07-20
  • Contact: Huang Changzheng

Abstract: 【Abstract】 Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis is a special type of dermatomyositis. It has characteristic clinical manifestations, mild myositis symptoms, and is prone to be accompanied by rapidly progressive interstitial lung disease, which indicates a poor prognosis. Its pathogenesis remains unclear, and may be related to genetic and environmental factors. This review summarizes progress in the treatment of anti-MDA5 antibody-positive dermatomyositis in recent years, in order to provide new ideas for its clinical treatment.

Key words: Dermatomyositis, Immunosuppressive therapy, Melanoma differentiation-associated gene 5, Anti-melanoma differentiation-associated gene 5 antibody, Interstitial lung disease